{"id":"W4213056115","doi":"10.3390/cancers14040915","title":"Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"PharmaMar; AstraZeneca España","keywords":"Olaparib; Medicine; Tolerability; Internal medicine; Oncology; Statistical significance; Ovarian cancer; Clinical trial; Phases of clinical research; Clinical significance; Gastroenterology; Cancer; Gene; Adverse effect; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002526741,0.001124084,0.002050665,0.000424788,0.0002265778,0.0009992964,0.0006367351,0.001136777,0.003370382],"category_scores_gemma":[0.001418307,0.000510664,0.001189397,0.0004088513,0.0006487831,0.000823589,0.0003563398,0.002594536,0.0006909447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000699924,"about_ca_system_score_gemma":0.001229748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002549563,"about_ca_topic_score_gemma":0.0006356161,"domain_scores_codex":[0.9991511,0.0005820722,0.00002928684,0.00009404253,0.00006525533,0.00007824228],"domain_scores_gemma":[0.9992099,0.000201399,0.0001919971,0.00005866157,0.00004289546,0.0002951182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.822261,0.03251071,0.01001105,0.001058816,0.001366264,0.0003346337,0.0001960463,0.001742758,0.03166705,0.0003945845,0.002997112,0.09545994],"study_design_scores_gemma":[0.6989717,0.2826229,0.01106401,0.0000593874,0.0004306857,0.0004175631,0.00003046762,0.001330458,0.001816498,0.0002383845,0.00298878,0.00002921287],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872612,0.005305781,0.0007466305,0.0008947764,0.0001515552,0.002081269,0.001392625,0.00009127981,0.002074858],"genre_scores_gemma":[0.9835728,0.002447536,0.002739192,0.00157896,0.0004679996,0.002687857,0.004274097,0.00003376822,0.00219787],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003370382,"threshold_uncertainty_score":0.01336288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02350924898876809,"score_gpt":0.332311343456145,"score_spread":0.3088020944673769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}